- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
United Cannabis Corporation Receives Notice of Allowance for New Patent Covering Methods of Preparing and Using Cannabinoid Formulations
Dec 12, 2019
Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD
May 22, 2020
India Lymphedema Treatment Market is expected to reach US$ 1,511.06 million by 2030
Oct 23, 2023
Radiopharmaceutical Theragnostics Market is expected to reach US$ 3,441.97 million by 2028
Mar 27, 2023
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Feb 13, 2020
US Mail Order Pharmacy Market is expected to reach US$ 1,71,883.03 million by 2030
Oct 16, 2023
NORTH AMERICA DRY EYE PRODUCT MARKET IS ANTICIPATED TO GROW WITH A CAGR OF 5.0% FROM 2019 TO 2027 , according to Business Market Insights
Jan 28, 2021